New pill for painful skin disease enters first human tests
NCT ID NCT07629336
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses in HS patients. The main goal is to check safety and how the drug moves through the body. About 114 participants will take part, and results will guide future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 5280001
RECRUITINGLeiden, 2333, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR447971 (also known as KT-485) – an oral tablet
What this could lead to
If successful, this could lead to a new oral treatment option for hidradenitis suppurativa, a painful skin condition.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not yet testing effectiveness. The drug may not work or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.